Loading data...
Loading data...
Analyzing the stock…
70
Gathering technical, fundamental, and market data — a few seconds
Health Care · ·
$42.91
▲ $0.17 (+0.4%)
Market data updated: 09/18 06:26 PM
Fundamentals updated: 09/18/2026
News analyzed: 09/18/2026
Market Cap
$2.50B
Day Range
$42.15 - $43.25
52-Week Range
$25.52 - $43.49
Beta
—
Next Earnings
02.11.2026
HRMY is a stock from the Healthcare sector — Pharmaceuticals, biotech, medical devices, and health insurance — less sensitive to economic cycles, but exposed to regulation and FDA approvals.
+31.5% (1Y)
Strengths: 23/32 factors positiveRisk: Medium
This score and all analysis on this page are for informational and educational purposes only and do not constitute investment advice. Read the full disclaimer
Weighted: Technical 25% · Fundamental 20% · Growth 15% · Valuation 15% · News 10% · Quality 10% · Risk 5%
Overall Score
🟢 Bullish
Technical Trend
🟢 Bullish
Insiders
🔴 Bearish
Computed directly from the same signals behind the score above — not AI-generated.
Biggest positive driver
DCF Fair Value
Estimated fair value: $161.68 vs. price $42.91 (+276.8%)
Fair Value
Biggest negative driver
Calmar Ratio (return vs. drawdown)
Calmar: 0.12 (3y annualized return 5.7% / max drawdown 48.6%)
Risk
What to watch next
When today echoes the past.
NO RELIABLE ECHO FOUND
Only 2 historical analog(s) found after removing overlapping dates — too few for a statistically meaningful comparison.
Historical matches considered: 2
TIME ECHO identifies historical situations that resemble the current market state. Historical outcomes are not guarantees of future performance. Similarity does not imply causation, and results may change as new data becomes available.
Harmony Biosciences (HRMY) exhibits a strong overall investor score of 77, underpinned by robust technical and fundamental metrics. The technical score of 94 reflects a clear bullish momentum, with the stock trading above both its 50-day and 200-day moving averages, a positive MACD histogram, and an RSI of 64.5 indicating healthy upward momentum. Fundamentally, the company demonstrates exceptional profitability, with gross margins at 77.2%, operating margins at 24.0%, and a strong ROA of 12.5%, all of which signal operational efficiency and profitability. Growth metrics are also noteworthy, particularly the 21.5% revenue growth and a staggering 59.1% increase in free cash flow, though EPS growth remains modest at 8.0%. Valuation appears highly attractive, with a fair value estimate of $161.68—nearly seven times the current price—though the NAV per share of $13.34 suggests potential undervaluation relative to liquidation value. News sentiment is mixed, with positive momentum post-earnings but a negative note regarding a poster presentation at a medical conference, which could indicate operational or strategic challenges. Quality metrics are decent, with stable operating margins and low leverage (debt-to-equity of 0.19), though volatility remains a concern, as evidenced by the low Kalman ratio (0.07) and a 50.8% historical drawdown. Overall, HRMY combines strong fundamentals and technical strength with significant valuation upside, though volatility and mixed news sentiment introduce caution.
The stock is trading above both its 50-day and 200-day moving averages, with a positive MACD histogram and an RSI of 64.5, indicating strong upward momentum and bullish technical conditions.
Strong technicals suggest near-term buying interest and potential for continued price appreciation.
Harmony Biosciences displays exceptionally high gross (77.2%) and operating margins (24.0%), alongside a strong ROA (12.5%), reflecting efficient operations and profitability.
High profitability margins and operational efficiency are critical for long-term sustainability and shareholder returns.
Revenue growth is robust at 21.5%, while free cash flow surged 59.1%, though EPS growth remains modest at 8.0% and net income growth is only 9.1%.
Strong cash flow growth is a positive signal for liquidity and reinvestment capacity, though slower EPS growth may limit near-term investor enthusiasm.
The stock trades at a significant discount to its estimated fair value ($161.68 vs. $42.07), with a P/E of 15.7 and a low NAV per share of $13.34, suggesting potential undervaluation.
A wide valuation gap could attract value investors, though it may also reflect market skepticism or uncertainty.
Recent news highlights positive post-earnings momentum but includes a negative note about a medical conference presentation, indicating mixed operational or strategic developments.
News sentiment can influence investor perception and volatility, particularly in biotech stocks where clinical or regulatory updates are critical.
Operating margins are stable or improving, and the company maintains low leverage (debt-to-equity of 0.19), though profitability metrics like ROE (18.2%) are only moderately strong.
Stable margins and low debt enhance financial resilience, but moderate ROE may limit investor confidence in shareholder returns.
The stock exhibits high volatility, with a low Kalman ratio (0.07), a 50.8% historical drawdown, and an ATR of 3.3% of the current price, signaling significant price swings.
High volatility increases risk exposure, particularly for investors sensitive to short-term price fluctuations.
StockIQ conclusion
Harmony Biosciences (HRMY) presents a compelling case for investors with a strong technical and fundamental foundation, supported by high profitability margins, robust revenue growth, and significant valuation upside. However, the stock’s high volatility, modest EPS growth, and mixed news sentiment introduce notable risks. The company’s ability to sustain free cash flow growth and deliver consistent clinical or operational updates will be critical in determining its long-term trajectory. While the data suggests a strong overall profile, investors should remain cautious of short-term volatility and the inherent uncertainties in the biotech sector.
Written automatically from the computed data shown on this page only — not investment advice.
🗓️ What Changed This Week
as of 09/11/202675
This Week
78
7D Ago
↓ -3
Weakening
Technical
89
7D Ago: 94
↓ -5
Fundamental
80
7D Ago: 83
↓ -3
Growth
70
7D Ago: 70
→ 0
Valuation
62
7D Ago: 62
→ 0
News
80
7D Ago: 86
↓ -6
Quality
63
7D Ago: 63
→ 0
Risk
54
7D Ago: 54
→ 0
Biggest Declines
📊 Score History
75
Today
—
30D
—
90D
—
1Y
🕰️ Signal Timeline
What StockIQ actually saw for this stock, and what happened after each signal — real data, not a forecast.
14d ago · $41.86
Evidence: -3.4pp vs. sector average today
What happened after
14d ago · $41.86
Evidence: המניה במגמת עלייה ברורה ללא טווח מסחר מוגדר בטווח הזמן שנבדק.
What happened after
14d ago · $41.86
Evidence: 11 bullish / 1 bearish technical signals agreeing
What happened after
16d ago · $40.92
Evidence: FOMO score jumped from 19 to 45 day-over-day
What happened after
🐂🐻 Investment Thesis
🐂 Bull Case
⚖️ Base Case
75 / 100
🐻 Bear Case
🔍 What Could Prove This Wrong
This isn't a price-direction forecast — just a synthesis of real, already-computed data, and future conditions that could change the picture.
🕰️ StockIQ Time Machine
What did StockIQ know — and when? Pick a date from the real accumulated history.
As of August 26, 2026
Then
73
$38.95
Now
75
$42.91
What happened since
Signals detected by this date
No signals detected by this date
🧬 STOCK DNA
This stock's profile across 8 real dimensions — a research tool, not a recommendation
Growth
70
Quality
63
Value
62
Momentum
89
Risk
54
Sentiment
80
Fundamental
80
Institutional
0
Stocks with a similar DNA right now
🕵️ What the Detective found on HRMY
Detective Score 80/100 · 3 signals convergingOverall, the signals found here lean positive.
🧠 What the Detective thinks
3 signals are currently converging on HRMY at once — see each one broken down below, in plain language, with its own positive/negative read.
What this means now: Several different technical indicators are currently agreeing on the same direction at once — that's unusual; most days they contradict each other.
Why it matters: When several technical indicators agree at once, that's usually more reliable than any single indicator alone.
What this means now: The price has formed a distinct technical structure (a trading range, shakeout, or breakout) that the Wyckoff method treats as a key moment where big money is building or unwinding a position.
Why it matters: May provide an additional indication of trading structure, but is not proof of future direction.
What this means now: The stock moved a lot more (or less) today than the average of other stocks in its sector — it stands out relative to its peers.
Why it matters: A move that meaningfully outpaces its sector suggests something company-specific, not just a sector-wide trend.
📊 Historically, this signal type
This is not a prediction and not investment advice — just a plain-language read of real, already-computed signals. Full details: Stock Detective →
This stock hasn't been analyzed by StockIQAI's movement engine yet — coverage is still expanding. Check back soon.
Recent media coverage of Harmony Biosciences Holdings, Inc. (HRMY) has primarily focused on its stock performance following earnings reports, which saw a 12.1% increase since the last update. The company also announced poster presentations at the 16th European Epilepsy Congress, highlighting progress in its trials for EPX-100 (clemizole hydrochloride) as a treatment for Dravet syndrome and Lennox-Gastaut syndrome. Additionally, Harmony Biosciences’ management team is set to participate in the 2026 Cantor Global Healthcare Conference.
AI summary based on English-language news sources only — not investment advice.
Everyone's writing about Harmony Biosciences Holdings, Inc.. News trend score: 80. Reason: 8 of the last 20 articles are positive, versus 3 negative.
News trend analysis is based on article sentiment only, and is not investment advice or financial counsel. Read the full disclaimer
🌡️ Emotional Temperature
33
🎯 Conviction (vs. Emotion)
42
Psychology
73
Fundamentals
80
Technical
89
Valuation
62
The price is holding at a real, documented historical support/resistance level (a 50-day high or low).
Price, volume, and sentiment accelerating together — a sign investors are chasing the price, not just following it.
Extreme momentum, price far above its moving average, and a large premium over fair value.
The price rise has far outpaced the actual improvement in fundamental data.
A sharp drop, unusual volume, and negative news sentiment all at once — selling pressure that looks emotional.
Price (3M)
+29%
Market Narrative
48
Fundamental Reality
42
Narrative Gap
+6
🔀 Psychology Acceleration
News attention/sentiment is running well ahead of the price move itself.
🧠 StockIQ Psychologist
HRMY’s psychology is dominated by **FOMO**, fueled by strong momentum (+5.8% ROC), elevated volume (1.36x avg), and positive sentiment (80/100). The stock trades near overbought RSI (66) and above Bollinger Band (+0.98), reinforcing urgency. However, euphoria (score 30) and anchoring (41) suggest investors may ignore valuation gaps (-74% vs. DCF), while overconfidence (8) hints at momentum-driven optimism over fundamentals. The key question: *Will traders sustain FOMO despite technical overbought conditions?*
Updated: 09/08/2026, 03:44 PM
What could change this?
👥 What the crowd believes
"Wolfe Initiates Harmony Biosciences at Outperform With $60 Price Target"
"presenting encore data from the company’s investigation of EPX-100 (clemizole hydrochloride) at the 16th European Epilepsy Congress"
📈 17D Investor Psychology
Signal classification confidence: High (confidence in the behavioral read, not a price prediction). Describes observable market behavior, not what any individual investor thinks, and is not a buy/sell signal.
🏛️ Investor DNA — Historical Investors
A Historical Strategy Simulation: assuming each investor follows their documented principles, how would they rate this stock today? This is not a prediction of what they would actually do.
🟢 Best match
Walter Bagehot — 100/100
🔴 Weakest match
Samuel Armstrong Nelson — 9/100
🗣️ Why do they disagree?
This stock sparks a sharp divide between methodologies, with some legendary investors seeing strong fundamentals while others flag red flags. Walter Bagehot’s near-perfect score highlights its liquidity resilience, suggesting it could weather financial stress, while Fisher, Livermore, and Smith all agree it’s a high-quality, long-term candidate—prioritizing durability, trend alignment, and decade-long potential. Meanwhile, Graham (both Defensive and Enterprising) and Housel lean cautiously positive, emphasizing its defensive merits and patient-holder appeal, though the Enterprising Investor’s stricter valuation bar still rejects it. On the flip side, Marks and Nelson warn of overvaluation or cyclical exhaustion, with Nelson’s low score signaling potential overbought conditions, while Lynch and the Efficient Market crowd dismiss it outright, questioning whether its growth justifies active selection over passive indexing. The contrast between Bagehot’s near-universal approval and Nelson’s dire warning underscores how the same stock can be framed as either a fortress or a speculative bubble depending on the lens.
Walter Bagehot
Lombard Street (1873)
🟢 100
Strong liquidity — would likely survive a real credit squeeze
Key question
Does this company have enough liquidity to survive real stress?
Fact → Principle → Simulation
Philip Fisher
Common Stocks and Uncommon Profits (1958)
🟢 84
Exceptional company quality by Fisher's standards
Key question
How exceptional is this business, really?
Fact → Principle → Simulation
Morgan Housel
The Psychology of Money (2020)
🟢 78
The kind of quiet compounder a patient holder could actually stick with
Key question
Could I live with this volatility long enough for compounding to actually work?
Fact → Principle → Simulation
Jesse Livermore
Reminiscences of a Stock Operator (1923) / How to Trade in Stocks (1940)
🟢 75
Positive trend — the price action Livermore looked for
Key question
What is the price telling me right now?
Fact → Principle → Simulation
Edgar Lawrence Smith
Common Stocks as Long-Term Investments (1924)
🟢 73
Looks like a real 'buy and hold for a decade' candidate
Key question
Is this a stock I'd be happy to hold and forget about for a decade?
Fact → Principle → Simulation
Benjamin Graham
Security Analysis (1934) / The Intelligent Investor (1949)
🟢 72
Attractive to a Defensive Graham Investor
Key question
Where is my margin of safety?
Fact → Principle → Simulation
Gerald M. Loeb
The Battle for Investment Survival (1935)
🟢 69
Reasonable capital-preservation profile
Key question
How much capital could I lose here if I'm wrong?
Fact → Principle → Simulation
Howard Marks
The Most Important Thing (2011) / Mastering the Market Cycle (2018)
🟡 61
Mixed — a good business, but expectations may already be high
Key question
What is the market probably misunderstanding about the risk here?
Fact → Principle → Simulation
Jack Schwager
Market Wizards (1989)
🟡 53
No clear edge either way
Key question
What's the risk/reward here, and where is my exit point?
Fact → Principle → Simulation
Charles Mackay
Extraordinary Popular Delusions and the Madness of Crowds (1841)
🟡 51
Some signs of crowd excitement building
Key question
Am I being swept along with the crowd, or thinking for myself?
Fact → Principle → Simulation
Burton Malkiel & John Bogle
A Random Walk Down Wall Street (1973) / The Little Book of Common Sense Investing (2007)
🟡 48
Mixed case — the evidence for picking this stock over an index is not strong
Key question
Do I actually have an edge here, or do I just think I do?
Fact → Principle → Simulation
Peter Lynch
One Up on Wall Street (1989)
🟡 42
Doesn't clear Lynch's growth-at-a-reasonable-price bar
Key question
Is the growth worth the price?
Fact → Principle → Simulation
Benjamin Graham (Enterprising Investor)
The Intelligent Investor (1949) — the Enterprising Investor chapters
🟡 41
Not statistically cheap enough for the Enterprising Investor's looser safety bar
Key question
Is the stock statistically cheap enough to justify the extra risk?
Fact → Principle → Simulation
Thorstein Veblen
The Theory of Business Enterprise (1904)
🟡 39
Pattern Veblen would flag as growth pursued for its own sake
Key question
Is management building real value, or just building itself?
Fact → Principle → Simulation
Howard Marks (Market Cycle)
Mastering the Market Cycle (2018)
🟡 39
Looks late-cycle — the position Marks would treat with extra caution
Key question
Where are we in the cycle right now — near a hot extreme, or a cold one?
Fact → Principle → Simulation
Samuel Armstrong Nelson
The ABC of Stock Speculation (1903)
🔴 9
Cycle looks stretched toward overbought
Key question
Is the price overextended, or is there still room to move?
Fact → Principle → Simulation
Based on the last 280 trading days, calculated from real price data. Click an indicator for details and a chart.
🟢 Most indicators support an uptrend (10 bullish · 1 bearish · 1 neutral)
A market-structure read based purely on real price and volume data — not full classic Wyckoff schematic identification (Phase A-E), but a quantitative analysis of what can reliably be computed: trading ranges, "effort vs. result", volume within the range, and Spring/Upthrust detection.
The stock is in a clear uptrend with no defined trading range in the period examined.
Medium confidence
The Wyckoff Method, developed by Richard Wyckoff in the early 20th century, reads the balance of supply and demand through price and volume, based on the premise that large investors ("smart money") quietly accumulate shares before rallies and quietly distribute them before declines. The read here is based solely on real price and volume data — full, precise identification of classic Wyckoff patterns (such as Phases A-E) requires human chart-reading experience and judgment, so this is an approximate algorithmic read, not a substitute for professional analysis. This should not be considered investment advice.
Gross Margin
77.2%
Operating Margin
24.0%
Net Margin
18.3%
EBITDA Margin
—
ROE
18.2%
ROA
12.5%
ROIC
—
EPS
$2.76
Cash
$752.50M
Total Debt
$163.66M
Current Ratio
3.60
Debt/Equity
0.19
How is Fair Value calculated? →
Current Price
$42.91
Estimated Fair Value (DCF)
$161.68
Model estimate — not a price target. Highly sensitive to growth/discount-rate assumptions.
Gap
+276.8%
🟢 Appears cheap relative to estimated value
Year 1 Growth Rate
25.0%
Discount Rate (WACC)
9.0%
Terminal Growth Rate
2.5%
Projection Years
5
| Year | Growth Rate | Projected FCF | Present Value |
|---|---|---|---|
| 1 | 25.0% | $434.86M | $398.96M |
| 2 | 19.4% | $519.12M | $436.93M |
| 3 | 13.8% | $590.49M | $455.97M |
| 4 | 8.1% | $638.47M | $452.31M |
| 5 | 2.5% | $654.43M | $425.34M |
Base FCF (last actual year)
$347.89M
Terminal Value
$10.32B
Present Value of Terminal Value
$6.71B
Enterprise Value
$8.88B
Net Debt
$-588.84M
Equity Value
$9.47B
*The DCF model is an estimate based on assumptions — not a guaranteed forecast. You can change the assumptions to examine different scenarios.
Book Value per Share
$15.07
Tangible Book Value per Share (Tangible NAV)
$13.53
Sentiment based on basic keywords (not AI) — 8 positive, 9 neutral, 3 negative out of the last 20 articles.
Benzinga · 10.9.2026
MT Newswires · 9.9.2026
Yahoo · 4.9.2026
Zacks · 4.9.2026
Yahoo · 3.9.2026
Zacks · 3.9.2026
Yahoo · 3.9.2026
GlobeNewswire · 3.9.2026
Yahoo · 27.8.2026
GlobeNewswire · 27.8.2026
Yahoo · 26.8.2026
The Fly · 26.8.2026
MT Newswires · 26.8.2026
Benzinga · 26.8.2026
Benzinga · 26.8.2026
SeekingAlpha · 19.8.2026
Yahoo · 14.8.2026
MarketBeat · 14.8.2026
Motley Fool · 11.8.2026
Yahoo · 11.8.2026
Harmony Biosciences Holdings, Inc. (HRMY) currently has a StockIQ AI score of 75/100, rated "Strong". The score is a weighted average across up to 7 categories (technical, fundamental, growth, fair value, news, quality, risk), based on real data only.
HRMY currently scores 75/100 (Strong) across the categories we measure. StockIQ doesn't give buy/sell recommendations — use this as one data point in your own research, not as investment advice.
Per StockIQ's DCF model, HRMY's estimated fair value is $161.68, which is 276.8% above the current price of $42.91. This is one valuation model among several signals in the fair-value category, not a price target.
HRMY's technical score is 89/100, which currently reads as bullish — based on real price/volume signals (moving averages, RSI, MACD, and more), not a prediction of what happens next.
Based on the real signals StockIQ computed: Estimated fair value: $161.68 vs. price $42.91 (+276.8%); Revenue growth (last year): 21.5%; Free cash flow growth: 59.1%.
Based on the real signals StockIQ computed: Calmar: 0.12 (3y annualized return 5.7% / max drawdown 48.6%); %K 87.2 — overbought.
StockIQ has no recorded dividend payment history for HRMY.
Real transactions by officers and insiders, as reported to the SEC on Form 4 — 0 purchases and 4 sales out of the last 25 filings.
| Name | Transaction Type | Date | Shares | Change | Price |
|---|---|---|---|---|---|
| Budur Kumar | Exercise of Derivative Securities | 8.9.2026 | 12,200 | +12,200 | $30.69 |
| Budur Kumar | Exercise of Derivative Securities | 8.9.2026 | 10,754 | -10,754 | — |
| Budur Kumar | Open Market Sale | 8.9.2026 | 22,954 | -22,954 | $43.10 |
| Budur Kumar | Exercise of Derivative Securities | 8.9.2026 | 12,200 | -12,200 | — |
| Budur Kumar | Exercise of Derivative Securities | 8.9.2026 | 10,754 | +10,754 | $30.27 |
| Budur Kumar | Open Market Sale | 8.9.2026 | 1,000 | -1,000 | $42.79 |
| Budur Kumar | Open Market Sale | 8.9.2026 | 4,500 | -4,500 | $42.25 |
| Budur Kumar | Open Market Sale | 4.9.2026 | 5,500 | -5,500 | $41.98 |
| Sender Gary | Grant/Award from Employer | 14.5.2026 | 21,872 | +21,872 | — |
| Sabater Juan A. | Grant/Award from Employer | 14.5.2026 | 21,872 | +21,872 | — |
| Graf R. Mark | Grant/Award from Employer | 14.5.2026 | 21,872 | +21,872 | — |
| Philip Ron M | Grant/Award from Employer | 14.5.2026 | 21,872 | +21,872 | — |
| Szyper Linda M | Grant/Award from Employer | 14.5.2026 | 21,872 | +21,872 | — |
| Germano Geno J | Grant/Award from Employer | 14.5.2026 | 21,231 | +21,231 | — |
| Germano Geno J | Grant/Award from Employer | 14.5.2026 | 21,231 | +21,231 | — |
| Graf R. Mark | Grant/Award from Employer | 14.5.2026 | 21,872 | +21,872 | — |
| Sender Gary | Grant/Award from Employer | 14.5.2026 | 21,872 | +21,872 | — |
| Szyper Linda M | Grant/Award from Employer | 14.5.2026 | 21,872 | +21,872 | — |
| Sabater Juan A. | Grant/Award from Employer | 14.5.2026 | 21,872 | +21,872 | — |
| Philip Ron M | Grant/Award from Employer | 14.5.2026 | 21,872 | +21,872 | — |
| Budur Kumar | Exercise of Derivative Securities | 1.5.2026 | 18,750 | -18,750 | — |
| Budur Kumar | Exercise of Derivative Securities | 1.5.2026 | 18,750 | +18,750 | — |
| Budur Kumar | Tax Withholding in Shares | 1.5.2026 | 8,882 | -8,882 | $31.83 |
| Budur Kumar | Exercise of Derivative Securities | 1.5.2026 | 32,997 | +18,750 | — |
| Budur Kumar | Tax Withholding in Shares | 1.5.2026 | 24,115 | -8,882 | $31.83 |
Official FINRA data — the number of shares open in short positions, plus daily short-sale activity.
5,164,996 shares short as of 2026-08-31 · vs. 4,496,943 on 2026-07-31
Official biweekly report (FINRA Rule 4560) — no real higher-frequency data exists for this metric.
74.3% of trading volume this week was short selling, vs. 70.6% the prior week
Based on daily short-sale volume (Reg SHO) — a different metric from the open short interest above: this is daily trading volume, not an open position, so it updates weekly rather than biweekly.
Full breakdown of every data type and its source: Data Sources · Methodology